NCT00619177

Assessing the Impact of MOVALIS in Osteoarthritis and Rheumatoid Arthritis Patients on Health Related Quality of Life

Assessing the Impact of MOVALIS on Health Related Quality of Life

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,569 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The objective of the observational study is to examine the effect of MOVALIS (Meloxicam) therapy on Health Related Quality of Life (HRQoL) in the diverse region of Central and Eastern Europe. The Medical Outcomes Study 12 Item Short Form Health Survey version 2 (SF-12v2) will be used as the instrument to measure any change in physical wellbeing (Physical Component Summary, PCS) and mental wellbeing (Mental Component Summary, MCS) of patients following MOVALIS (Meloxicam) therapy.

Conditions

• Osteoarthritis
• Arthritis, Rheumatoid

Timeline

• Start date: 2007-03-01
• Primary completion: 2008-05-01
• First posted: 2008-02-20
• Last updated: 2015-02-16
• Results posted: 2009-11-18

Locations

319 sites across 5 countries: Croatia, Czechia, Estonia, Russia, Slovakia